Close Menu

NEW YORK – Biotech company NKMax America said on Tuesday that the US Food and Drug Administration had accepted its investigational new drug application for studying its natural killer cell therapy SNK01 in combination with trastuzumab (Genentech/Roche's Herceptin) or cetuximab (Eli Lilly's Erbitux) for the treatment of advanced or metastatic HER2 or EGFR-expressing cancers.

The company now plans to start a Phase I/II open-label, multicenter trial in the third quarter of 2020.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.